Font Size: a A A
Keyword [BRAFv600E]
Result: 21 - 40 | Page: 2 of 5
21. The Correlation Of BRAFV600E Point Mutations And Ki-67 Protein Expression In Papillary Thyroid Carcinoma
22. The Relationship Of The Expression Of PD-L1, BRAFV600E, And CD68 With Malignant Melanoma
23. Papillary Thyroid Carcinoma Is Regulated By TET3 Through 5hmC And BRAF Modification
24. The Expression Of MiRNA363 And BRAFV600E In Papillary Thyroid Microcarcinoma And The Mechanism Of MiRNA63 In The Progression Of Thyroid Papillary Carcinoma
25. The Correlation Of 25-hydroxy VitaminD3 And Insulin Resistance With Papillary Thyroid Carcinoma
26. Correlation Between Sonographic Characteristics Of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastases And BRAFV600E Mutation
27. Paper One: A Case Of Erythrodermic Psoriasis Inward With Staphylococcus Aureus Septicemia Paper Two: Encorafenib(LGX818),A Potent BRAF Inhibitor,Induces Senescence Accompanied By Autophagy In Brafv600e Melanoma Cells
28. The Effect Of C-met Inhibitor PHA-665752 Combined With Vemurafenib On Growth Of BRAFV600E Mutant Colon Cancer Xenografts
29. The Proteomic Analysis Of Exosomes From The BRAFV600E Mutant Colon Cancer Cell Line
30. Clinical Significance Of BRAF And RAS Mutations In Thyroid Papillary Carcinoma
31. Value And Correlation Between The Thyroid Imaging Reporting And Data System And BRAFV600E Mutation
32. Clinical Significace Of BRAFV600EMutation In Differentiating The Benign From The Malignant Thyroid Tumor
33. Relationship Between BRAFV600E Gene And TERT Promoter Mutations And Cervical Lymph Node Metastasis In Papillary Thyroid Carcinoma
34. BRAFV600E And RET/PTC Promote Proliferation And Migration Of Papillary Thyroid Carcinoma By Regulating Nuclear Factor-?B
35. STAT3 Inhibition Enhances Vemurafenib Sensitivity In Colon Cancers Harboring A BRAFV600E Mutation
36. Diagnostic Role Of Three-Dimensional System Of Sonographic Image,Cytopathology-histopathology And Molecular Profile For Thyroid Carcinoma
37. The Role And Mechanism Of SiRNABRAFV600ECarried By Targeted Nanobubbles For Papillary Thyroid Cancer With Cervical Lymph Node Metastasis
38. Targeting Therapy For Differentiated Thyroid Cancer
39. BRAF Gene Mutation Based Recurrent Risk Analysis And Target Therapy Optimization In Papillary Thyroid Carcinoma
40. The Study Of Conventional Ultrasound Combined With Molecular Markers In Predicting Lymph Node Metastasis In Central Cervical Area Of ??papillary Thyroid Carcinoma
  <<First  <Prev  Next>  Last>>  Jump to